Allergan, Inc.

Thomas K Karami

Scott W Smith

Ke Wu

Shaoxin Feng

Fiona Dubas-Fisher

Adrian St Clair Brown

Richard S Graham

Anuradha V Gore

Gyorgy F Ambrus

The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as 'tromethamine salt of bimatoprost acid.' The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.

Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof

The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as 'bimatoprost acid.' The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.

Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof

The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as 'tromethamine salt of bimatoprost acid.' The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.

Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof

The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.

Crystalline form of cyclosporine A, methods of preparation, and methods for use thereof

The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.

Growing community of inventors

Aliso Viejo, CA, United States of America

Thomas K Karami